A proteinogenic amino acid derivative resulting from the formal reaction of L-cysteine at the amino group, carboxy group, or thiol group, or from the replacement of any hydrogen of L-cysteine by a heteroatom.
ChEBI ID: 83824
| Member | Definition | Role |
|---|---|---|
| acetylcysteine | An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine. | N-acetyl-L-cysteine |
| cilastatin | The thioether resulting from the formal oxidative coupling of the thiol group of L-cysteine with the 7-position of (2Z)-2-({[(1S)-2,2-dimethylcyclopropyl]carbonyl}amino)hept-2-enoic acid. It is an inhibitor of dehydropeptidase I (membrane dipeptidase, 3.4.13.19), an enzyme found in the brush border of renal tubes and responsible for degrading the antibiotic imipenem. Cilastatin is therefore administered (as the sodium salt) with imipenem to prolong the antibacterial effect of the latter by preventing its renal metabolism to inactive and potentially nephrotoxic products. Cilastatin also acts as a leukotriene D4 dipeptidase inhibitor, preventing the metabolism of leukotriene D4 to leukotriene E4. | cilastatin |
| cysteinesulfenic acid | A cysteine derivative consisting of L-cysteine carrying an S-hydroxy-substituent. | S-hydroxy-L-cysteine |
| cystine | The L-enantiomer of the sulfur-containing amino acid cystine. | L-cystine zwitterion; L-cystine |
| djenkolic acid | A dithioacetal consisting of two molecules of L-cysteine joined via their sulfanyl groups to methylene. | L-djenkolic acid |
| glutathione sulfonate | glutathione sulfonate | |
| pantothenylcysteine 4'-phosphate | The N-[(R)-4-phosphopantothenoyl] derivative of L-cysteine. | N-[(R)-4-phosphopantothenoyl]-L-cysteine |
| s-farnesylcysteine alpha-carboxyl methyl ester | An alpha-amino acid ester that is the methyl ester of S-[(2E,6E)-farnesyl]-L-cysteine. | S-[(2E,6E)-farnesyl]-L-cysteine methyl ester |
| s-nitrosocysteine | An L-cysteine derivative in which the sulfur atom carries a nitroso substituent. A cell-permeable low-molecular-weight nitrosothiol and nitric oxide donor. | S-nitroso-L-cysteine |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1,628 (10.65) | 18.7374 |
| 1990's | 2,325 (15.21) | 18.2507 |
| 2000's | 4,536 (29.67) | 29.6817 |
| 2010's | 5,342 (34.95) | 24.3611 |
| 2020's | 1,455 (9.52) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 1,317 (8.20%) | 5.53% |
| Reviews | 1,072 (6.67%) | 6.00% |
| Case Studies | 631 (3.93%) | 4.05% |
| Observational | 29 (0.18%) | 0.25% |
| Other | 13,019 (81.02%) | 84.16% |